Scarica l'app Stockscreener
2.83
3.41%
-0.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.93
Aprire:
$2.92
Volume 24 ore:
266.00K
Relative Volume:
0.51
Capitalizzazione di mercato:
$182.46M
Reddito:
-
Utile/perdita netta:
$-45.08M
Rapporto P/E:
-3.8767
EPS:
-0.73
Flusso di cassa netto:
$-33.68M
1 W Prestazione:
-14.50%
1M Prestazione:
-30.64%
6M Prestazione:
-21.39%
1 anno Prestazione:
+126.40%
Intervallo 1D:
$2.76
$2.95
Intervallo di 1 settimana:
$2.76
$3.28
Portata 52W:
$1.12
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Nome
Galectin Therapeutics Inc
Settore
Industria
Telefono
678-620-3186
Indirizzo
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Confronta GALT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.83 | 188.91M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-13 | Iniziato | B. Riley FBR | Buy |
| 2017-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-19 | Iniziato | ROTH Capital | Buy |
| 2017-03-30 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Downgrade | ROTH Capital | Buy → Sell |
| 2016-03-28 | Ripresa | H.C. Wainwright | Buy |
| 2015-09-21 | Iniziato | H.C. Wainwright | Buy |
| 2014-08-01 | Downgrade | Aegis Capital | Buy → Hold |
| 2014-07-30 | Reiterato | MLV & Co | Buy |
| 2014-07-29 | Reiterato | MLV & Co | Buy |
| 2014-04-02 | Reiterato | MLV & Co | Buy |
| 2014-02-10 | Reiterato | Aegis Capital | Buy |
| 2014-01-09 | Reiterato | Aegis Capital | Buy |
| 2013-12-03 | Iniziato | MLV & Co | Buy |
| 2013-08-19 | Reiterato | Aegis Capital | Buy |
Mostra tutto
Galectin Therapeutics Inc Borsa (GALT) Ultime notizie
Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap dropped US$39m last week; Individual investors bore the brunt - simplywall.st
What’s the outlook for Galectin Therapeutics Inc.’s sectorJuly 2025 Recap & Weekly Momentum Picks - mfd.ru
Stock Market Recap: Can Galectin Therapeutics Inc expand into new marketsJobs Report & Real-Time Volume Analysis - baoquankhu1.vn
Meme Stocks: Will Galectin Therapeutics Inc outperform its industry peersMarket Activity Report & Expert Approved Momentum Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc.GALT - yourwyominglink.com
Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders - Yahoo Finance
Analysis Recap: Can Galectin Therapeutics Inc be the next market leaderTrade Entry Report & Smart Investment Allocation Insights - baoquankhu1.vn
Moving Averages: What is the Moat Score of WVVIPBuy Signal & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Update - MarketBeat
Galectin Therapeutics Under Investigation, Stock Plummets 28.9% - Intellectia AI
Is Galectin Therapeutics Inc. gaining market shareJuly 2025 Analyst Calls & Safe Entry Point Identification - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Galectin Therapeutics Inc. (GALT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Insider Buy: Can BROG navigate macro headwindsWeekly Investment Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Growth Review: Is Galectin Therapeutics Inc stock affected by interest rate hikesQuarterly Earnings Report & Daily Growth Stock Investment Tips - Bộ Nội Vụ
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Galectin Therapeutics Inc. (GALT) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Galectin Therapeutics director Marc Rubin resigns from board By Investing.com - Investing.com India
Galectin Therapeutics announces board resignation of Marc Rubin - TipRanks
Galectin Therapeutics director Marc Rubin resigns from board - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeutics Inc. (GALT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Will Galectin Therapeutics Inc. stock continue dividend increasesJuly 2025 Closing Moves & Detailed Earnings Play Strategies - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Therapeutics Inc. (GALT) And Encourages Investors to Connect - ACCESS Newswire
Galectin Therapeutics Inc.'s (NASDAQ:GALT) Last Week's 23% Decline Must Have Disappointed Individual Investors Who Have a Significant Stake - 富途牛牛
Can Galectin Therapeutics Inc. (PHPN) stock sustain institutional flowsJuly 2025 Drop Watch & AI Enhanced Execution Alerts - Улправда
Is Galectin Therapeutics Inc. (PHPN) stock a safe buy pre earningsJuly 2025 Spike Watch & Fast Gain Swing Trade Alerts - Улправда
Will Galectin Therapeutics Inc. stock benefit from automationJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - Улправда
Fraud Investigation Opened: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Shareholders - ACCESS Newswire
Is Galectin Therapeutics Inc. stock resilient to inflationJuly 2025 Review & Precise Swing Trade Entry Alerts - Улправда
How buybacks impact Galectin Therapeutics Inc. stock value2025 Momentum Check & Consistent Return Strategy Ideas - Улправда
MACD Signal: Will Galectin Therapeutics Inc. stock benefit from automation2025 Technical Overview & Community Consensus Trade Alerts - Улправда
Is Galectin Therapeutics Inc. stock attractive for income investors2025 Growth vs Value & High Win Rate Trade Tips - Улправда
Institution Moves: Will Galectin Therapeutics Inc. (PHPN) stock beat Nasdaq index returnsJuly 2025 Earnings & Safe Investment Capital Preservation Plans - ulpravda.ru
Market Trends: Will Galectin Therapeutics Inc PHPN stock beat Nasdaq index returnsJuly 2025 Retail & Real-Time Volume Analysis Alerts - Bộ Nội Vụ
Fraud Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Shareholders - ACCESS Newswire
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Galectin Therapeutics CFO sells $233k in shares By Investing.com - Investing.com UK
Galectin Therapeutics CFO sells $233k in shares - Investing.com
Insider Sell: Jack Callicutt Sells 60,000 Shares of Galectin The - GuruFocus
Khurram Jamil Sells 21,446 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) CFO Sells $58,438.80 in Stock - MarketBeat
Insider Selling: Galectin Therapeutics (NASDAQ:GALT) CEO Sells 18,571 Shares of Stock - MarketBeat
Joel Lewis Sells 27,731 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Insider Khurram Jamil Sells 13,055 Shares - MarketBeat
Insider Selling: Galectin Therapeutics (NASDAQ:GALT) CFO Sells 20,354 Shares of Stock - MarketBeat
Galectin Therapeutics Faces Securities Fraud Investigation as Stock Plummets 28.9% - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin ... - Bluefield Daily Telegraph
Should I hold or sell Galectin Therapeutics Inc. stock in 20252026 world cup usa national team qualification top scorers build up play knockout prediction preview - Улправда
Galectin Therapeutics (NASDAQ:GALT) CEO Joel Lewis Sells 37,698 Shares - MarketBeat
Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Galectin Therapeutics reveals promising NAVIGATE trial results - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Galectin Therapeutics Inc. (GALT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Galectin Therapeutics Inc Azioni (GALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):